Clinical Trial

Testing Treatment for Prostate Cancer

Study Description

Feasibility Trial in Men With Hormone Sensitive Oligometastatic Prostate Cancer

Patients with hormone sensitive oligometastatic prostate cancer (a?$ 5 metastatic tumours outside of regional pelvic nodes with no more than 3 in any organ system) and no previous treatment to prostate will be treated with intermittent androgen deprivation therapy +/- chemotherapy, stereotactic radiotherapy to all metastases, and either radical prostatectomy or radiotherapy.

Location

Locations Selected Location

Methods

No pharmaceutical medication involved No pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Procedure - Radical prostatectomy

Radical prostatectomy

Radiation - HDR (19Gy) or SBRT (35-40Gy)

Patients will receive HDR unless judged to medically unfit to undergo HDR brachytherapy, in which case they will receive SBRT

Additional Information

Official Study Title

Randomized Feasibility Trial of Prostate Radiotherapy vs Prostatectomy in Men With Hormone Sensitive Oligometastatic Prostate Cancer

Clinical Trial ID

NCT03301701

ParticipAid ID

QeZ1vd